Medicare fraud whistleblowers to share in $5.25M

Medicare fraud whistleblowers will get a share of the $5.25 million settlement reached between the United States Department of Justice and a major pharmacy chain.  RxAmerica, a subsidiary of CVS Caremark, settled claims that it misrepresented the cost of prescription drugs to seniors under Medicare part D. Under the False Claims Act, a whistleblower receives a percentage of any monies recovered by the government.  The amount a whistleblower could receive ranges from 15 to 30 percent of the total monetary recovery by the government. If you have non-public information about Medicare fraud or...

read more

Ghost Patient Medicaid Fraud: NV woman sentenced

Medicaid fraud ghost patients A common form of Medicaid and Medicare fraud is the use of what is called ghost patients.  Health care providers submit claims to the government for health care services, medical devices, medical tests, pharmaceuticals, or procedures they never provide.  Either the patients do not exist at all, or the patients exist but did not receive the health care. If you have non-public information about ghost patient Medicaid fraud or other health care fraud, a whistleblower attorney can help you determine whether you have a case.  We can help evaluate whether you may be...

read more

Medicare Fraud Fought With New Tools

The Affordable Care Act, widely called “Obamacare,” provides new tools and funding for combatting Medicare fraud and Medicaid fraud.  The purpose is to reduce the costs of fraud to the government and taxpayers.  NPR explains: Medicare and Medicaid pay out some $750 billion each year to more than 1.5 million doctors, hospitals and medical suppliers. By many estimates, about $65 billion a year is lost to fraud…. Criminals use real patient IDs to bill for wheelchairs that were never delivered or exams never performed.  Dishonest doctors — a small percentage of physicians,...

read more

GlaxoSmithKline to Pay $3 Billion in Pharmaceutical Whistleblower Case

Pharmaceutical company GlaxoSmithKline has agreed to pay $3 billion in fines to the government in a pharmaceutical whistleblower case.  This is the largest pharmaceutical fraud settlement to date, and brings whistleblower lawsuit settlements to a total of $10 billion for 2012.  Whistleblowers get a share of these settlements as a reward for reporting fraud under the False Claims Act. The pharmaceutical whistleblowers were four GSK employees, including a vice president and a senior marketing development manager.  The pharmaceutical fraud involved GSK’s conduct regarding Paxil,...

read more

Facebook